Esperion Therapeutics, Inc. (ESPR) financial statements (2020 and earlier)

Company profile

Business Address 3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20113620021221210660
Cash and cash equivalents166373438778557
Short-term investments3599166173135214
Other undisclosed current assets11742211
Total current assets:21214320421421410761
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment1101110
Long-term investments and receivables 07331803618
Long-term investments 07331803618
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Total noncurrent assets:317432813718
TOTAL ASSETS:21414327824529614378
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4148226233
Accounts payable2945205122
Accrued liabilities1231111 
Employee-related liabilities     01
Deferred revenue2
Debt0 1221 
Other liabilities     00
Other undisclosed current liabilities2316118221
Total current liabilities:66643316654
Noncurrent Liabilities
Long-term debt and lease obligation1  134 
Long-term debt, excluding current maturities   134 
Operating lease, liability1
Other undisclosed noncurrent liabilities127      
Total noncurrent liabilities:128  134 
Total liabilities:1946433178104
Stockholders' equity
Stockholders' equity attributable to parent, including:207924522928713474
Common stock0000000
Additional paid in capital715678642458442238142
Accumulated other comprehensive income (loss)0(0)(1)(0)(0)(0)(0)
Accumulated deficit(695)(598)(396)(229)(154)(104) 
Other undisclosed stockholders' equity attributable to parent      (68)
Total stockholders' equity:207924522928713474
TOTAL LIABILITIES AND EQUITY:21414327824529614378

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:148      
Operating expenses(241)(205)(169)(76)(50)(36)(23)
Operating loss:(93)(205)(169)(76)(50)(36)(23)
Nonoperating income
(Other Nonoperating income)
4322100
Interest and debt expense(8) (0)(0)(1)(0)(1)
Net loss:(97)(202)(167)(75)(50)(36)(24)
Other undisclosed net loss attributable to parent      (3)
Net loss available to common stockholders, diluted:(97)(202)(167)(75)(50)(36)(26)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(97)(202)(167)(75)(50)(36)(24)
Comprehensive loss:(97)(202)(167)(75)(50)(36)(24)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent01(1)0(0)(0)(3)
Comprehensive loss, net of tax, attributable to parent:(97)(201)(168)(75)(50)(36)(26)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: